Date: 2017-03-21
Type of information: R&D agreement
Compound: fully human monoclonal antibody candidates
Company: Pierre Fabre (France) H-Immune (France)
Therapeutic area: Cancer - Oncology
Type agreement: research development
Action mechanism: monoclonal antibody
Disease:
Details: * On March 21, 2017, Pierre Fabre and H-Immune, an emerging biotechnology company focused on developing first in class immunotherapies for treatment of various cancers, announced that they have entered into a strategic research partnership which will utilize H-Immune’s technology platform to generate lead candidates of fully human antibodies to serve as the initial step in a program to develop immuno-oncology therapeutics. As a newly established bioscience company in the immuno-oncology field and spin out from the French Atomic Energy Commission, H-Immune has developed a proprietary In Vitro Immunization (IVI) technology leveraging a breakthrough approach to generate a series of fully human monoclonal antibodies against any therapeutic target, taking advantage of the affinity maturation processes performed in situ by B lymphocytes. Under the terms of the agreement, Pierre Fabre will have access to H-Immune’s IVI technology for three different discovery programs in the field of immuno-oncology.
Financial terms: The financial terms of the agreement, which include expertise contribution, R&D funding, and milestone payments to H-Immune, were not disclosed.
Latest news:
